Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar;10(6):304. doi: 10.21037/atm-22-556

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2022 Annals of Translational Medicine. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

DBH-AS1 expression correlates with beneficial outcomes in gemcitabine-treated patients with PC. (A) qPCR analysis of DBH-AS1 expression in PDX samples. (B) PDXs expressing low or high levels of DBH-AS1 treated for 28 days with gemcitabine (30mg/kg body weight) or vehicle control, with tumor growth rates monitored over time. (C) Schematic demonstrating the mechanisms through which DBH-AS1 suppresses pancreatic cancer cell growth and gemcitabine resistance. (A,B) t-test. Data are means ± SEM from triplicate experiments, *, P<0.05; NS, P>0.05. PC, pancreatic cancer; qPCR, quantitative polymerase chain reaction; PDX, patient-derived xenograft; NS, no statistical.